Health ❯Healthcare ❯Cancer Research
Tumor Immune Evasion Cancer Treatment Mathematical Modeling Immune Checkpoint Inhibitors Pembrolizumab Therapeutic Targets Glypican-3 Targeting
The novel agent produced high-contrast PET/MR scans in a 36-patient trial without any reported side effects.